These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 18463532)

  • 1. Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma.
    Hofmann MA; Kors C; Audring H; Walden P; Sterry W; Trefzer U
    J Immunother; 2008 Jun; 31(5):520-7. PubMed ID: 18463532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma.
    Pashenkov M; Goëss G; Wagner C; Hörmann M; Jandl T; Moser A; Britten CM; Smolle J; Koller S; Mauch C; Tantcheva-Poor I; Grabbe S; Loquai C; Esser S; Franckson T; Schneeberger A; Haarmann C; Krieg AM; Stingl G; Wagner SN
    J Clin Oncol; 2006 Dec; 24(36):5716-24. PubMed ID: 17179105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intradermal CpG-B activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patients.
    Molenkamp BG; van Leeuwen PA; Meijer S; Sluijter BJ; Wijnands PG; Baars A; van den Eertwegh AJ; Scheper RJ; de Gruijl TD
    Clin Cancer Res; 2007 May; 13(10):2961-9. PubMed ID: 17504997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, pharmacokinetics and immune effects in normal volunteers of CPG 10101 (ACTILON), an investigational synthetic toll-like receptor 9 agonist.
    Vicari AP; Schmalbach T; Lekstrom-Himes J; Morris ML; Al-Adhami MJ; Laframboise C; Leese P; Krieg AM; Efler SM; Davis HL
    Antivir Ther; 2007; 12(5):741-51. PubMed ID: 17713157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma.
    Weber JS; Zarour H; Redman B; Trefzer U; O'Day S; van den Eertwegh AJ; Marshall E; Wagner S
    Cancer; 2009 Sep; 115(17):3944-54. PubMed ID: 19536884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients.
    Molenkamp BG; Sluijter BJ; van Leeuwen PA; Santegoets SJ; Meijer S; Wijnands PG; Haanen JB; van den Eertwegh AJ; Scheper RJ; de Gruijl TD
    Clin Cancer Res; 2008 Jul; 14(14):4532-42. PubMed ID: 18628468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of secondary structure of toll-like receptor 9 agonists on interferon alpha induction.
    Yu D; Putta MR; Bhagat L; Dai M; Wang D; Trombino AF; Sullivan T; Kandimalla ER; Agrawal S
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4320-5. PubMed ID: 18852281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo effects of CpG-Oligodeoxynucleotides (CpG-ODN) on murine transitional cell carcinoma and on the native murine urinary bladder wall.
    Olbert PJ; Schrader AJ; Simon C; Dalpke A; Barth P; Hofmann R; Hegele A
    Anticancer Res; 2009 Jun; 29(6):2067-76. PubMed ID: 19528466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of the intratumoral administration of recombinant canarypox viruses expressing B7.1 and interleukin 12 in patients with metastatic melanoma.
    Triozzi PL; Allen KO; Carlisle RR; Craig M; LoBuglio AF; Conry RM
    Clin Cancer Res; 2005 Jun; 11(11):4168-75. PubMed ID: 15930353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients.
    Ren T; Wen ZK; Liu ZM; Qian C; Liang YJ; Jin ML; Cai YY; Xu L
    Cancer Invest; 2008 Jun; 26(5):448-55. PubMed ID: 18568766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An exploratory study of systemic administration of the toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma.
    Dummer R; Hauschild A; Becker JC; Grob JJ; Schadendorf D; Tebbs V; Skalsky J; Kaehler KC; Moosbauer S; Clark R; Meng TC; Urosevic M
    Clin Cancer Res; 2008 Feb; 14(3):856-64. PubMed ID: 18245549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/beta2-microglobulin DNA-liposome complex, in patients with metastatic melanoma.
    Stopeck AT; Jones A; Hersh EM; Thompson JA; Finucane DM; Gutheil JC; Gonzalez R
    Clin Cancer Res; 2001 Aug; 7(8):2285-91. PubMed ID: 11489803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthetic methylated CpG ODNs are potent in vivo adjuvants when delivered in liposomal nanoparticles.
    Chikh G; de Jong SD; Sekirov L; Raney SG; Kazem M; Wilson KD; Cullis PR; Dutz JP; Tam YK
    Int Immunol; 2009 Jul; 21(7):757-67. PubMed ID: 19502586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toll-like receptor 9 mediates CpG oligonucleotide-induced cellular invasion.
    Ilvesaro JM; Merrell MA; Li L; Wakchoure S; Graves D; Brooks S; Rahko E; Jukkola-Vuorinen A; Vuopala KS; Harris KW; Selander KS
    Mol Cancer Res; 2008 Oct; 6(10):1534-43. PubMed ID: 18922969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary invasive melanoma and basal cell carcinoma (collision tumor) with blue nevus-like cutaneous metastases.
    King R; Lyons J; Meyers AL; Googe PB; Page RN; Gupta VK
    J Cutan Pathol; 2007 Aug; 34(8):629-33. PubMed ID: 17640233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma.
    Link BK; Ballas ZK; Weisdorf D; Wooldridge JE; Bossler AD; Shannon M; Rasmussen WL; Krieg AM; Weiner GJ
    J Immunother; 2006; 29(5):558-68. PubMed ID: 16971811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma.
    Kim YH; Girardi M; Duvic M; Kuzel T; Link BK; Pinter-Brown L; Rook AH
    J Am Acad Dermatol; 2010 Dec; 63(6):975-83. PubMed ID: 20888065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CpG-ODN-based immunotherapy is effective in controlling the growth of metastasized tumor cells.
    Kim HA; Ko HM; Ju HW; Kim KJ; Roh SG; Lee HK; Im SY
    Cancer Lett; 2009 Feb; 274(1):160-4. PubMed ID: 18952369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists.
    Vollmer J; Krieg AM
    Adv Drug Deliv Rev; 2009 Mar; 61(3):195-204. PubMed ID: 19211030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011-vcMMAE) targeting GPNMB.
    Pollack VA; Alvarez E; Tse KF; Torgov MY; Xie S; Shenoy SG; MacDougall JR; Arrol S; Zhong H; Gerwien RW; Hahne WF; Senter PD; Jeffers ME; Lichenstein HS; LaRochelle WJ
    Cancer Chemother Pharmacol; 2007 Aug; 60(3):423-35. PubMed ID: 17541593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.